Please enter both email and password to log in
You need to upgrade your Flash Player
|
You need to upgrade your Flash Player to view this content.
What's New?
New CME-certified case study!
The Role of Nonpharmacologic and Lipid-Lowering Therapies in a Patient With Low Framingham-Assessed Cardiovascular Risk. M. Dominique Ashen, PhD, CRNP, and CCMD Faculty Member Roger S. Blumenthal, MD, explore nonpharmacologic and lipid-lowering treatments for a patient with evidence of increased cardiovascular risk beyond that suggested by Framingham Risk Scoring. Earn 0.75 AMA PRA Category 1 Credit™ and access to an anthology of CCMD slides instantly!
|
OnsiteInsight® from AHA Scientific Sessions 2008!
This issue of OnsiteInsight® highlights clinical-trial results and scientific sessions focusing on issues in the management of atherosclerosis from the American Heart Association Scientific Sessions 2008 in New Orleans! Also featured: expert commentary from CCMD Education Council Member JoAnne M. Foody, MD.
|
New Slides on JUPITER data
Check out our latest slides featuring an NHANES extrapolation of the population meeting JUPITER study eligibility.
|
Daily Updates from ADA 2009
Read daily summaries and expert insights on data presented at the American Diabetes Association 69th Scientific Session in New Orleans.
|
In the News
New Product For Pfizer Specialty Takes Pulmonary Arterial Hypertension To Heart
Jul 02, 2009 -- Pfizer Australia announced that it has signed an agreement to acquire the local distribution rights for THELIN (Sitaxentan sodium), an oral, once-daily highly selective endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA/WHO Functional Class III symptoms to improve exercise ability. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease1.
|
New Product For Pfizer Specialty Takes Pulmonary Arterial Hypertension To Heart
Jul 02, 2009 -- Pfizer Australia announced that it has signed an agreement to acquire the local distribution rights for THELIN (Sitaxentan sodium), an oral, once-daily highly selective endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA/WHO Functional Class III symptoms to improve exercise ability. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease1.
|
|
|
|
|
CCMD Co-Chairmen
|
Education Council
George L. Bakris, MD
|
Elizabeth Barrett-Connor, MD
|
Keith C. Ferdinand, MD
|
JoAnne M. Foody, MD
|
Peter Ganz, MD
|
Philip B. Gorelick, MD, MPH
|
Scott M. Grundy, MD, PhD
|
Steven M. Haffner, MD
|
Ronald M. Krauss, MD
|
John C. LaRosa, MD
|
Peter Libby, MD
|
Thomas A. Pearson, MD, MPH, PhD
|
|
|